

AtriCure, Inc.
Form 8-K
January 14, 2015

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

of the SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 14, 2015

ATRICURE, INC.

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction

of incorporation)

000-51470
(Commission

File Number)

34-1940305
(IRS Employer

Identification No.)

6217 Centre Park Drive

45069

West Chester, OH
(Address of principal executive offices) **(Zip Code)**
Registrant's telephone number, including area code: (513) 755-4100

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective January 14, 2015, Douglas J. Seith, age 49, was appointed Chief Operating Officer of AtriCure, Inc. (the Company). Mr. Seith has over 25 years of cardiology and general surgery sales and sales leadership experience and has served as AtriCure s Senior Vice President, Sales and Marketing since January 2013. Mr. Seith has held a variety of progressive sales and sales leadership positions since joining AtriCure in 2004. In connection with this appointment, Mr. Seith shall continue to be eligible to participate in the Company s compensation plans and arrangements as a named executive officer in the discretion of the Compensation Committee of the Board of Directors.

A copy of the press release announcing the appointment of Mr. Seith is furnished as Exhibit 99.1 and incorporated by reference in this Item 5.02.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

No.	Description
99.1	Press Release dated January 14, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATRICURE, INC.

Dated: January 14, 2015

By: /s/ M. Andrew Wade
M. Andrew Wade
Senior Vice President and Chief Financial Officer